251 286 - Biotech Bayern

Contact:
Prof. Dr. Gottfried Brem
Thalmannsdorf 25, Larezhausen
D-86567 Hilgertshausen
Phone: +49 (0) 8250 928466
Fax: +49 (0) 8250 7166
E-Mail: gbremabg@apogene-gmbh.de
Internet: www.apogene-gmbh.de
ARTHROGEN GmbH
Contact:
Priv.-Doz. Dr. med. Ulrich Schneider
Wiesseerstr. 103
D-83707 Ringsee
Phone: +49 (0) 8022 187978
Fax: +49 (0) 8022 187978
E-Mail: info@arthrogen.de
Internet: www.arthrogen.de
Contact:
Yvonne Deppert
Moosstr. 7
D-82319 Starnberg
Phone: +49 (0) 8151 44690-22
Fax: +49 (0) 8151 44690-30
E-Mail: kontakt@prostrakan.com
Internet: www.arzneimittel-prostrakan.de
42
apoGene GmbH & Co. KG
BIOTECH AGRO, FOOD, ENVIRONMENT
Keywords: Tissue Engineering / Cell Culture, Knock Out, Xenotransplantation
apoGene is focused on the field of xenotransplantation. Rabbits and pigs are
genetically modified (transfer, knock out and recombination of endogenous
genes) for influencing the different steps of the rejection process after
xenotransplantation of animals tissues and organs. We are also investigating the
expression of endogenous retroviral sequences after xenogenetic transfer.
For the development of knock out animals we have developed and patented
an alternative strategy, the so called screen-out of hemozygote carriers of
functional defects in natural or mutagenized populations. The technique will
also be very interesting for the establishment of animal models for basic and
applied research.
ARTHROGEN GmbH
PHARMA & CHEMICAL INDUSTRY
Arthrogen combines scientific and clinical know-how in order to successfully
develop innovative gene therapeutic approaches for the treatment of patients
with rheumatic diseases.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by
persistent joint swelling and progressive destruction of cartilage and bone.
Among the connective diseases RA is the commonest and the most important in
socioeconomic terms. Biologicals targeting specific cytokines and their receptors
have been proven useful as systemic therapies for RA and provide proof
of principle of targeted therapies. Gene therapy can provide stable, regulated
production of anti-inflammatory molecules and might provide a more efficient
system to deliver therapeutic compounds at the site of inflammation. Local
gene therapy for chronic diseases such as RA could permit long-term production
of therapeutic molecules in the inflamed compartment.
Arzneimittel ProStrakan GmbH
PHARMA & CHEMICAL INDUSTRY
Keywords: Drug Development, Drug Delivery, Cardiovascular Diseases,
Endocrinology, Metabolic Diseases, Oncology, Pain
Arzneimittel ProStrakan GmbH is the German affiliate of the Scottish ProStrakan Ltd,
a pan-European pharmaceutical company. ProStrakan is engaged in the development
and commercialisation of speciality prescription medicines for the treatment
of unmet therapeutic needs.
In Germany the core products to date were in the field of mineral nutrients and
generics for cardiovascular diseases, diabetes and lipometabolism. In 2007 two
innovative products were launched, one for the treatment of anal fissures, the other
for the treatment of testosterone deficiency. Further innovative products (cancer
pain, post operative nausea and vomiting, etc.) will be launched in 2008.